Evidence mapPaperPMID 35668155Full record

ArticleInflammation2022

Ulinastatin Alleviates Rhabdomyolysis-Induced Acute Kidney Injury by Suppressing Inflammation and Apoptosis via Inhibiting TLR4/NF-κB Signaling Pathway.

Jinxiang Wang, Guowu Xu, Heng Jin, Yanfen Chai, Xinyue Yang, Ziquan Liu, Shike Hou, Haojun Fan

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Food science & nutrition · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. New Therapeutic Method for Alleviating Damage of Acute Kidney Injury ThroughInternational journal of molecular sciences · 2024
    Article
  13. Engineered urolithin A-laden functional polymer-lipid hybrid nanoparticles prevent cisplatin-induced proximal tubular injury in vitro.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jinxiang Wang *Wenzhou Safety (Emergency) Institute of Tianjin University, Wenzhou, Zhejiang, 325000, China. wangjx_192@tmu.edu.cn.ORCID http://orcid.org/0000-0002-4717-8549
Guowu Xu *Wenzhou Safety (Emergency) Institute of Tianjin University, Wenzhou, Zhejiang, 325000, China.
Heng Jin *Wenzhou Safety (Emergency) Institute of Tianjin University, Wenzhou, Zhejiang, 325000, China.
Yanfen ChaiDepartment of Emergency Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xinyue YangInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin, 300072, China.
Ziquan LiuWenzhou Safety (Emergency) Institute of Tianjin University, Wenzhou, Zhejiang, 325000, China.
Shike HouWenzhou Safety (Emergency) Institute of Tianjin University, Wenzhou, Zhejiang, 325000, China.
Haojun FanWenzhou Safety (Emergency) Institute of Tianjin University, Wenzhou, Zhejiang, 325000, China. fanhaojun999@126.com.
Wenzhou University · CNTianjin Medical University General Hospital · CNTianjin University · CN

Funding

Nationale National Natural Science Foundation of China 82072222Scientific Research Program of Tianjin Education Commission 2021KJ211the Scientific Research Translational Foundation of Wenzhou Safety (Emergency) Institute of Tianjin University TJUWYY2022022
6 · The paper itself

Abstract

Acute kidney injury (AKI) is an important complication of rhabdomyolysis (RM), but there is lack of effective treatments. Ulinastatin (UTI) is a broad-spectrum serine protease inhibitor isolated and purified from human urine with strong anti-inflammatory and cytoprotective actions. The aim of this research was to investigate the effect and potential mechanism of UTI on RM-induced AKI (RM-AKI). We established RM-induced AKI model and myoglobin (Mb)-stimulated NRK-52E cell model. In vivo, twenty-four rats were randomly divided into three groups (n = 8): control, RM-AKI, and RM-AKI + UTI. In vitro, the NRK-52E cells were divided into six groups according to the different treatment method. Mb-stimulated NRK-52E cells were treated with UTI or si-TLR4 transfection to characterize the mechanisms of UTI in RM-AKI. Indicators of the kidney injury, cell viability, cell cycle, oxidative stress, inflammation, apoptosis, and TLR4/NF-κB signaling pathway were assessed. In vivo and in vitro, UTI significantly decreased the expression of TLR4 and p65. In vivo, UTI significantly improved renal function and reduced inflammatory reaction and kidney injury. In vitro, UTI protected NRK-52E cells from Mb stimulation by suppressing cell cytotoxicity, cell cycle inhibition, overproduction of ROS, inflammation, and apoptosis. Additionally, UTI played a protective role by downregulating the TLR4 expression. The results indicate that UTI alleviates RM-AKI by suppressing the inflammatory response and apoptosis via inhibiting TLR4/NF-κB signaling pathway. Our study provides a new mechanism for the protective effect of UTI on RM-AKI.

Indexed as

Acute Kidney InjuryRhabdomyolysisAnimalsAnti-Inflammatory AgentsApoptosisGlycoproteinsHumansInflammationKidneyMyoglobinNF-kappa BRatsReactive Oxygen SpeciesSerine Proteinase InhibitorsSignal TransductionToll-Like Receptor 4Anti-Inflammatory AgentsGlycoproteinsMyoglobinNF-kappa BReactive Oxygen SpeciesSerine Proteinase InhibitorsTLR4 protein, humanTlr4 protein, ratToll-Like Receptor 4urinastatinacute kidney injuryapoptosisinflammationrhabdomyolysisTLR4/NF-κBulinastatin

Identifiers

PMID35668155
OpenAlexW4281613462

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.